Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/35554
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKhor, Yet H-
dc.contributor.authorJohannson, Kerri A-
dc.contributor.authorMarcoux, Veronica-
dc.contributor.authorFisher, Jolene H-
dc.contributor.authorAssayag, Deborah-
dc.contributor.authorManganas, Helene-
dc.contributor.authorKhalil, Nasreen-
dc.contributor.authorKolb, Martin-
dc.contributor.authorRyerson, Christopher J-
dc.date.accessioned2024-10-21T05:18:48Z-
dc.date.available2024-10-21T05:18:48Z-
dc.date.issued2024-10-15-
dc.identifier.citationAmerican journal of respiratory and critical care medicine 2024-10-15; 210(8)en_US
dc.identifier.issn1535-4970-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/35554-
dc.description.abstractRationale: Cough is a key symptom in patients with fibrotic interstitial lung disease (ILD). Objectives: This study evaluated the prevalence, longitudinal change, associations, and prognostic significance of cough severity in patients with fibrotic ILD. Methods: We included consecutive patients with idiopathic pulmonary fibrosis (IPF) and non-IPF fibrotic ILD who completed the 100-mm Cough Severity Visual Analog Scale from the prospective multicenter Canadian Registry for Pulmonary Fibrosis. Baseline cough severity and associations with patient demographics and clinical factors were determined. Relationships between baseline cough severity and health outcomes were evaluated. Measurements and Main Results: Patients with IPF (n = 1,061) had higher median baseline cough severity than those with non-IPF fibrotic ILD (n = 2,825) (24 vs. 20 mm; P < 0.001), with worse cough associated with gastroesophageal reflux disease for both cohorts. Worse cough severity was independently associated with worse health-related quality of life at baseline, larger annualized decline in DlCO, development of disease progression, and reduced transplant-free survival in both IPF and non-IPF fibrotic ILD cohorts. The IPF cohort (2.2 mm; 95% confidence interval, 1.6-2.9 mm) had larger annualized increments in cough severity than the non-IPF fibrotic ILD cohort (1.1 mm; 95% confidence interval, 0.8-1.4 mm; P = 0.004). There was no difference in worsening cough over time comparing those receiving and not receiving ILD-targeted therapy or with and without lung function decline. Conclusions: Cough is common in patients with IPF and non-IPF fibrotic ILD, with increasing cough severity over time irrespective of ILD-targeted therapy. Patient-reported cough severity has prognostic implications on health-related quality of life, disease progression, and survival in fibrotic ILD.en_US
dc.language.isoeng-
dc.subjectchronic coughen_US
dc.subjectcoughen_US
dc.subjecthealth outcomesen_US
dc.subjectidiopathic pulmonary fibrosisen_US
dc.subjectinterstitial lung diseaseen_US
dc.titleEpidemiology and Prognostic Significance of Cough in Fibrotic Interstitial Lung Disease.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleAmerican journal of respiratory and critical care medicineen_US
dc.identifier.affiliationRespiratory and Sleep Medicineen_US
dc.identifier.affiliationInstitute for Breathing and Sleepen_US
dc.identifier.affiliationDepartment of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.en_US
dc.identifier.affiliationDepartment of Medicine, University of Toronto, Toronto, Ontario, Canada.en_US
dc.identifier.affiliationDepartment of Medicine, McGill University, Montreal, Quebec, Canada.en_US
dc.identifier.affiliationDépartement de Médecine, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.en_US
dc.identifier.affiliationDepartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.en_US
dc.identifier.affiliationDepartment of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, Ontario, Canada; and.en_US
dc.identifier.affiliationDepartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.;Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada.en_US
dc.identifier.doi10.1164/rccm.202311-2101OCen_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-5434-9342en_US
dc.identifier.orcid0000-0003-1205-5511en_US
dc.identifier.orcid0000-0002-2497-9984en_US
dc.identifier.orcid0000-0003-3837-1467en_US
dc.identifier.pubmedid38536110-
dc.description.volume210-
dc.description.issue8-
dc.description.startpage1035-
dc.description.endpage1044-
dc.subject.meshtermssecondaryCough/etiology-
dc.subject.meshtermssecondaryCough/physiopathology-
dc.subject.meshtermssecondaryCough/epidemiology-
dc.subject.meshtermssecondaryLung Diseases, Interstitial/physiopathology-
dc.subject.meshtermssecondaryLung Diseases, Interstitial/epidemiology-
dc.subject.meshtermssecondaryLung Diseases, Interstitial/mortality-
dc.subject.meshtermssecondaryCanada/epidemiology-
dc.subject.meshtermssecondaryIdiopathic Pulmonary Fibrosis/epidemiology-
dc.subject.meshtermssecondaryIdiopathic Pulmonary Fibrosis/physiopathology-
dc.subject.meshtermssecondaryIdiopathic Pulmonary Fibrosis/complications-
dc.subject.meshtermssecondaryIdiopathic Pulmonary Fibrosis/mortality-
item.languageiso639-1en-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.cerifentitytypePublications-
crisitem.author.deptRespiratory and Sleep Medicine-
crisitem.author.deptInstitute for Breathing and Sleep-
crisitem.author.deptMedicine (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

20
checked on Nov 6, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.